Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort
Caroline Huber, Jeremy Pomeroy, ANDREA HAQQ, Nicolas Touchot et al.
Journal
Obesity
Topics
Genetic and Kidney Cyst Diseases
article
Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort
Caroline Huber, Jeremy Pomeroy, ANDREA HAQQ, Nicolas Touchot, Jan Luca Schorfheide, Jesús Argente, Urs Wiedemann, the Phase 3 BBS Trial Investigators
article en
Abstract
No abstract available for this paper.
Publication Tag
ObesityVol. 34(3)
Institutions
Madrid Institute for Advanced Studies (ES), University of Alberta (CA), Instituto de Salud Carlos III (ES), Jazz Pharmaceuticals (United States) (US), Hospital Infantil Universitario Niño Jesús (ES), Hospital Universitario de La Princesa (ES), Marshfield Clinic (US), Instituto de Investigación en Ciencias de la Alimentación (ES), European Patent Organisation (DE), Rhythm (United states) (US), Universidad Autónoma de Madrid (ES)
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
Setmelanotide in Bardet‐Biedl Syndrome: A 52‐Week Comparison of Phase 3 Trial Participants With a Matched Registry Cohort — Caroline Huber, Jeremy Pomeroy, et al. · Obesity (2026) | TGRS Research Map | TGRS